# Follistatin 344

> Follistatin 344 is one of two naturally occurring isoforms of follistatin, a glycoprotein that binds and neutralizes activin and other TGF-beta superfamily members, most notably myostatin, a primary negative regulator of muscle mass. It gained attention following animal studies in which overexpression produced pronounced increases in skeletal muscle size. As a synthetic research peptide, it is studied for its potential to counteract myostatin-driven limits on muscle growth. Human data are sparse, and most supporting evidence comes from cell culture and animal gene-therapy models rather than peptide-dosing trials in people.

- URL: https://www.lifeconverted.com/peptides/follistatin-344
- Also known as: FST-344, FS344
- Primary category: Muscle & Performance
- Effectiveness rank: #15 in Healing & Recovery; #6 in Muscle & Performance
- Evidence level: Emerging research
- Route: Subcutaneous (Some research protocols use intramuscular injection at the target muscle for a more localized effect.)
- Dose range: 100-300 mcg
- Dose tiers: low 100 mcg; moderate 200 mcg; high 300 mcg
- Half-life: Estimated at several hours; precise human pharmacokinetic data are not well established
- Timing: Morning
- Cycle: 4-8 weeks on, 8-12 weeks off (Given the lack of long-term human safety data, conservative and infrequent cycling is generally discussed rather than continuous use.)
- Storage: Store lyophilized peptide frozen or refrigerated away from light; reconstitute with bacteriostatic water and keep refrigerated, using within 2-3 weeks.

## Mechanism of action

Follistatin 344 binds directly to myostatin (GDF-8) and related activins, preventing them from engaging the activin type IIB receptor and blocking the downstream Smad2/3 signaling that normally suppresses muscle protein synthesis and satellite cell activity. Because the 344 isoform carries a heparin-binding domain, it associates more readily with cell-surface proteoglycans, concentrating its activity near tissue surfaces. This is proposed to shift muscle growth signaling toward hypertrophy.

## Reported benefits

- Proposed reduction of myostatin-mediated suppression of muscle growth
- Suggested support for satellite cell activation and muscle repair
- Interest as an adjunct in research settings focused on preserving lean mass
- Broader activin inhibition that may affect other TGF-beta-regulated tissues

## Reported side effects

- Unknown long-term safety profile in humans
- Theoretical risk from broad inhibition of activin/TGF-beta signaling, which regulates reproductive and other tissues
- Injection site reactions
- Possible unpredictable effects given non-selective binding across the TGF-beta superfamily

## Common protocols

- Daily subcutaneous injection cycles of several weeks
- Research protocols modeled loosely on animal-study dosing, scaled down and heavily hedged for human extrapolation

## Stacking notes

Sometimes discussed alongside IGF-1 analogs in research contexts aiming to combine myostatin inhibition with direct anabolic signaling; no established human data support or refute such combinations.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer